Bimagrumab Phase 2 trial (NCT06643728)
A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study of Bimagrumab and Tirzepatide, Alone or in Combination, to Investigate the Efficacy and Safety in Adult Participants With Obesity or Overweight Without Type 2 Diabetes
Registry record checked
At a glance
- Phase
- Phase 2
- Status
- Active, not recruiting
- Enrolment
- 252
- actual
- Start
- 21 Oct 2024 (actual)
- Primary completion
- 16 Jan 2026 (actual)
- Sponsor
- Eli Lilly and Company
Design
Arms and doses
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Part A: Bimagrumab Dose 2 + Tirzepatide Placebo | Experimental | Drug: Bimagrumab; Drug: Tirzepatide Placebo | Participants will receive bimagrumab subcutaneously (SC) and tirzepatide placebo SC |
| Part A: Bimagrumab Placebo + Tirzepatide Dose 1 | Active comparator | Drug: Tirzepatide; Drug: Bimagrumab Placebo | Participants will receive bimagrumab placebo SC and tirzepatide SC |
| Part A: Bimagrumab Placebo + Tirzepatide Dose 2 | Active comparator | Drug: Tirzepatide; Drug: Bimagrumab Placebo | Participants will receive bimagrumab placebo SC and tirzepatide SC |
| Part A: Bimagrumab Dose 1 + Tirzepatide Dose 1 | Experimental | Drug: Bimagrumab; Drug: Tirzepatide | Participants will receive bimagrumab SC and tirzepatide SC |
| Part A: Bimagrumab Dose 1 + Tirzepatide Dose 2 | Experimental | Drug: Bimagrumab; Drug: Tirzepatide | Participants will receive bimagrumab SC and tirzepatide SC |
| Part A: Bimagrumab Dose 2 + Tirzepatide Dose 2 | Experimental | Drug: Bimagrumab; Drug: Tirzepatide | Participants will receive bimagrumab SC and tirzepatide SC |
| Part A: Bimagrumab Placebo + Tirzepatide Placebo | Placebo comparator | Drug: Bimagrumab Placebo; Drug: Tirzepatide Placebo | Participants will receive bimagrumab placebo SC and tirzepatide placebo SC |
| Part B: Bimagrumab Dose 2 (no titration) + Tirzepatide Dose 1 | Experimental | Drug: Bimagrumab; Drug: Tirzepatide | Participants will receive bimagrumab SC and tirzepatide SC |
| Part B: Bimagrumab Dose 2 (fast titration) + Tirzepatide Dose 1 | Experimental | Drug: Bimagrumab; Drug: Tirzepatide | Participants will receive bimagrumab SC and tirzepatide SC |
| Part B: Bimagrumab Dose 2 (slow titration) + Tirzepatide Dose 1 | Experimental | Drug: Bimagrumab; Drug: Tirzepatide | Participants will receive bimagrumab SC and tirzepatide SC |
| Part B: Bimagrumab Dose 1 + Tirzepatide Placebo | Experimental | Drug: Bimagrumab; Drug: Tirzepatide Placebo | Participants will receive bimagrumab SC and tirzepatide placebo SC |
| Part B: Bimagrumab Placebo + Tirzepatide Placebo | Placebo comparator | Drug: Bimagrumab Placebo; Drug: Tirzepatide Placebo | Participants will receive bimagrumab placebo SC and tirzepatide placebo SC |
Endpoints
Primary endpoint
| Measure | Time frame |
|---|---|
| Percent Change from Baseline in Body Weight | Baseline, Week 24 |
Endpoints
Key secondary endpoints
The first secondary outcomes listed on the registry record.
| Measure | Time frame |
|---|---|
| Percent Change from Baseline in Total Body Fat Mass by Dual-Energy X-Ray Absorptiometry (DXA) | Baseline, Week 24, Week 48 |
| Change from Baseline in Body Weight | Baseline, Week 24, Week 48 |
| Percentage of Participants Achieving ≥5% Body Weight Reduction | Baseline, Week 24, Week 48 |
| Percentage of Participants Achieving ≥10% Body Weight Reduction | Baseline, Week 24, Week 48 |
| Percentage of Participants Achieving ≥15% Body Weight Reduction | Baseline, Week 24, Week 48 |
| Change from Baseline in Waist Circumference | Baseline, Week 24, Week 48 |
| Change from Baseline in Body Mass Index (BMI) | Baseline, Week 24, Week 48 |
| Change from Baseline in Waist-to-Height Ratio (WHtR) | Baseline, Week 24, Week 48 |
| Percent Change from Baseline in Visceral Adipose Tissue (VAT) | Baseline, Week 24, Week 48 |
| Percent Change from Baseline in Total Body Lean Mass by DXA | Baseline, Week 24, Week 48 |
Eligibility
Who could enrol
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Results
Results
No results posted on ClinicalTrials.gov as of 2 Oct 2026.
Sources
- 1A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study of Bimagrumab and Tirzepatide, Alone or in Combination, to Investigate the Efficacy and Safety in Adult Participants With Obesity or Overweight Without Type 2 DiabetesClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026
Found an error? Report a correction.